We present a case report of an 18-year-old female who presented to the hospital with a biparietal subacute headache that progressed with paresthesias and behavioral changes like mutism, inattention, hypersomnia, and myoclonus. Her physical examination revealed mixed dysarthric speech (flaccid and spelled), dyscalculia, and altered abstraction. She underwent an electroencephalogram that showed the presence of mild generalized dysfunction, without epileptiform activity. Imaging studies and a lumbar puncture did not support the diagnosis of infectious pathology. The Bush Francis score was rated 1 and a MOCA test 17, revealing cognitive impairment. Anti-NMDA and Anti-GAD65 antibodies were reported in the cerebrospinal fluid autoantibodies panel. She started treatment with methylprednisolone plus sessions of plasmapheresis, which finally showed improvement and she was discharged, but within less than two months she had a relapse of neuropsychiatric symptoms and was admitted again. Thus rituximab treatment was initiated as a second-line option that resulted in good clinical evolution and no signs of relapse in the following 2 months.